Pharmacological agents, such as ACE inhibitors (ramipril) and ARBs (valsartan), help alleviate DCM by inhibiting angiotensin II signalling, thereby suppressing the TGF-β and MAPK pathways and reducing myocardial fibrosis and hypertrophy. The gene discussed is TGFB1; the disease is Myocardial fibrosis.